EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

Oslo, Norway, 24 June 2025. EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

The trial is a multi-centre, open-label Phase 2 clinical trial testing the safety and efficacy of Acoustic Cluster Therapy (ACT®) in combination with standard of care (modified FOLFIRINOX chemotherapy) in first line patients with borderline resectable or unresectable locally advanced pancreatic cancer.

“We are excited to have the first pancreatic cancer patient treated with ACT at our first U.S. site. More than 500,000 patients are diagnosed with pancreatic cancer each year globally, and pancreatic cancer is one of the deadliest types of cancer, with limited and often ineffective treatment options. This trial addresses the significant unmet medical need and the urge to advance novel treatment options for this patient population. We are on track with the opening of sites for patient recruitment and initial safety data are expected in 2025.” said Per Walday, Chief Executive Officer of EXACT Therapeutics.

Dosing of the first patient in the Phase 2 trial follows the announcement of positive final efficacy and safety data in the Phase 1 trial in patients with liver metastases of colorectal origin.

The Phase 2 trial will enroll up to 25 patients in the U.S., U.K. and Europe, and has the ClinicalTrials.gov Identifier: NCT06850623.